ATRC

NEUTRALTechnical

AtriCure, Inc.

2026-09-21

Price

$58.32

+0.38%

This is the 2026-09-21 snapshot — the signals and analysis for ATRC as of this single trading day.

View full ATRC research hub →

Score3.8Watchlist

Signals4/8 DNA0/13 Act · 2/4 Risk

SentimentNEUTRALScore: 8

Volume0.7xvs 20d avg

Analysis

AtriCure (ATRC) is demonstrating High-Conviction Price Discovery, fueled by a confluence of institutional accumulation, an upgrade from Weiss Ratings, and today's S&P index rebalancing. The stock's pristine technical setup—highlighted by SURGE, PERFECT_STACK, and MARKET_LEADER signals—aligns perfectly with raised FY2026 guidance and heavy 13F fund buying. Amplified by a definitive RISK_ON macro regime and a broader rotation into medical devices, ATRC's +17.9% relative strength against the SPY confirms it is aggressively leading the tape rather than just drifting.

Fired Signals

SURGEGOLDEN CROSSMARKET LEADERPERFECT STACKEXTENSIONDISTRIBUTION

Key Takeaways

Actionable Thesis: Capitalize on High-Conviction Price Discovery driven by institutional accumulation, raised FY2026 guidance, and S&P index rebalancing flows.
Key Risk: Valuation concerns raised by some analysts and potential post-rebalance exhaustion could cap near-term upside.
What to Watch: Monitor volume follow-through post-rebalance and the $48.17 line-in-the-sand to validate ongoing structural support.

← Back to 2026-09-21 View Full ATRC History →Yahoo Finance &nearr;